Nucleus Network Begins Clinical Trial of COVID-19 Antibody Treatment
15 September 2020 Release date 11 September 2020 Australia’s largest Phase 1 clinical trials specialist, Nucleus Network, has this week started the first human trials of a potential COVID-19 treatment developed by Singlomics (Beijing DanXu) Biopharmaceuticals and licensed…
University accelerates the process of 3D printed nasal swabs for COVID-19 testing
15 September 2020 Release date 11 September 2020 The University of Melbourne has brought together industry partners and researchers for the development of an Australian-first; locally manufactured 3D printed nasal swab for coronavirus (COVID-19) testing. 3DMEDiTECH, a partner…
Positive results flow continues for Dimerix’s DMX-200 kidney disease therapy candidate
14 September 2020 In what has been a steadily positive research progression so far, Melbourne-based clinical-stage biopharmaceutical company Dimerix has reported a continuation of strong clinical trial results for its drug candidate DMX-200, which is aimed at a…
Medtronic Study Finds Opioid-Induced Respiratory Depression in the Hospital More Common and Costly
14 September 2020 Release date 10 September 2020 PRODIGY Study Provides First Validated Risk Prediction Tool to Guide Continuous Monitoring for Opioid-Induced Respiratory Depression (OIRD) OIRD Occurred in 46% of Patients Studied Patients with Respiratory Depression Are 37%…
Gilead Sciences to Acquire Immunomedics
13 September 2020 Gilead Adds TrodelvyTM, First-in-Class Antibody-Drug Conjugate Approved to Treat Triple-Negative Breast Cancer, With Promise in Other Forms of Breast Cancer and Additional Solid Tumors Acquisition Transforms Gilead’s Portfolio with First-in-Class Commercial Product with Significant Revenue and…
Electronic Signatures and Clinical Trial Research Agreement execution in Australia
14 September 2020 Release date 12 September 2020 CT:IQ together with Medicines Australia (MA), Medical Technology Association of Australia (MTAA) and AusBiotech have released a joint position statement confirming that eSignatures can be used to execute clinical trial…
Levitas Bio partners with Planet Innovation to develop and manufacture the world’s first label-free cell separation platform
14 September 2020 Silicon Valley start-up Levitas Bio has launched the world’s first label-free cell separation platform, the LeviCell™. The benchtop device uses revolutionary magnetic levitation technology developed at Stanford University to sort cell populations, without modifying the cells with…
Opthea Appoints US-Based Non-Executive Director
10 September 2020 The directors of Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, are pleased to announce the appointment of Mr Daniel Spiegelman as an…
Locked And Loaded: Using Genomic Sequencing To Target Covid-19’s Weak Spots
10 September 2020 Originally published via the University of Melbourne by Stephanie Portelli, Elston D’Souza and Associate Professor David Ascher COVID-3D, a new open-access tool harnesses SARS-CoV-2 genomic and structural information to help ensure therapeutic efforts remain effective.…
Noxopharm Appoints New Chair
10 September 2020 Release date 9 September 2020 Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announces the appointment of Mr Fred Bart as Non-Executive Chair, allowing ExecutiveChair and CEO, Dr Graham Kelly, to focus on the CEO…
Global CRO To Execute Noxopharm DARRT-2 Prostate Cancer Study
10 September 2020 Release date 8 September 2020 Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce that after a rigorous global search, the clinical research organisation (CRO), Parexel® Biotech, has been appointed to manage…
Allens: Capturing the hydrogen opportunity for Australia and Japan
10 September 2020 Now is the time to look for future global opportunities Australia’s hydrogen industry is expected to contribute at least $11 billion to the national economy and generate around 7,600 jobs by 2050. In the current state of play,…
